Gut Microbiome Enzymes

Gut Microbiome Enzymes refer to the extensive array of catalytic proteins encoded by the collective genomes of the human gut microbiota [5, 10]. These enzymes play a fundamental role in human health by facilitating the digestion of complex carbohydrates, synthesizing essential vitamins like K and B12, and modulating the host's immune and metabolic systems [11, 13]. However, specific microbial enzymes are also linked to the development of diseases; for example, microbial trimethylamine (TMA) lyases contribute to cardiovascular disease by producing TMA, which is later converted to the pro-atherogenic metabolite TMAO [12, 19]. Additionally, enzymes like beta-glucuronidase can interfere with drug safety by reactivating glucuronidated drug metabolites in the gut, causing localized toxicity [4, 7]. Because of their significant impact on host physiology and pharmacology, gut microbiome enzymes are increasingly viewed as viable therapeutic targets [3, 15]. Current and emerging strategies involve using small-molecule inhibitors to selectively block harmful enzymatic activities or utilizing microbial enzymes to activate prodrugs [1, 19]. This targeted approach aims to treat metabolic, inflammatory, and oncological conditions while minimizing the broad ecological disruption typically associated with traditional antibiotics [6, 15]. By focusing on specific enzymatic pathways, researchers hope to develop precision therapies that modulate the chemical output of the microbiome for improved patient outcomes [5, 9].

Other names

Gut microbial enzymesMicrobiota-derived enzymesCommensal enzymesXenobiotic-metabolizing enzymes of the gut

Selective inhibition of microbial enzymes to prevent toxic metabolite formation, prodrug activation via microbial cleavage, and modulation of host metabolic pathways through altered microbial metabolite production [1, 4, 7, 19].